ArticleThe Journal of experimental medicine2020
Genetic manipulation of LKB1 elicits lethal metastatic prostate cancer.
Article in The Journal of experimental medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Clinicopathological and prognostic significance of LKB1 expression in gastric cancer: a systematic review and meta-analysis.Scientific reports · 2023Pooled it
- Targeting CRTC2 reversesProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Aggressive prostate cancer is associated with pericyte dysfunction.Molecular oncology · 2026Article
- Epigenetic plasticity and chemoresistance in cancer: mechanisms, biomarkers, and translational opportunities for real-world evidence.Frontiers in cell and developmental biology · 2026Review
- Pan-Cancer Computational Analysis of RKIP (International journal of molecular sciences · 2025Article
- LKB1 inactivation unleashes prostate cancer lineage plasticity.Cell research · 2025Article
- The role of LKB1 in prostate cancer: implications for tumor progression and therapy.Frontiers in cell and developmental biology · 2025Review
- LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer.Cell research · 2025Article
- Metastatic hormone-naïve prostate cancer: a distinct biological entity.Trends in cancer · 2024Review
- The PP2A regulator IER5L supports prostate cancer progression.Cell death & disease · 2024Article
- CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression.Nature communications · 2024Article
- The role of STK11/LKB1 in cancer biology: implications for ovarian tumorigenesis and progression.Frontiers in cell and developmental biology · 2024Review
- STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.Molecular cancer · 2023Article
- Interplay of Developmental Hippo-Notch Signaling Pathways with the DNA Damage Response in Prostate Cancer.Cells · 2022Review
- LKB1 deficiency upregulates RELM-α to drive airway goblet cell metaplasia.Cellular and molecular life sciences : CMLS · 2021Article
- PIM kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating LKB1.Cell communication and signaling : CCS · 2021Article
- Dependency of human and murine LKB1-inactivated lung cancer on aberrant CRTC-CREB activation.eLife · 2021Article
- MiRNA-145-5p expression and prospective molecular mechanisms in the metastasis of prostate cancer.IET systems biology · 2021Article
- Insights into Urological Cancer.Cancers · 2021Article
- In Vivo Assessment of Metastatic Cell Potential in Prostate Cancer.Methods in molecular biology (Clifton, N.J.) · 2021Article
Corrections and comments
- Commented on by
Authors and funding
35 authors at 12 institutions in 3 countries.
Funding
Abstract
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.